Brief: XtalPi & PharmaEngine Hit Milestone as PRMT5 Inhibitor PEP08 Gets Trial Nod
09/09/2025 13:44
Sept 9 (Reuters) - XtalPi Holdings Ltd 2228.HK: XTALPI AI DRUG DISCOVERY COLLABORATION REACHES MILESTONE AS PHARMAENGINE'S NOVEL PRMT5 INHIBITOR PEP08 RECEIVES CLINICAL TRIAL APPROVALS Source text: ID:nPn2myz5ka Further company coverage: 2228.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on XtalPi Holdings
See all newsBrief: XtalPi Announces Strategic Partnership With Potential Deal Value Over $400 Mln
Brief: Xtalpi To Repurchase Shares Up To $100 Million
Brief: XtalPi Receives Second Payment From DoveTree Under Strategic Collaboration
Brief: XtalPi Says Subsidiary Buys Structured Deposits For RMB356.1 MLN On Sept 11
Brief: Xtalpi Holdings Posts FY Profit Attributable RMB123.7 Million